NDC product
CUVITRU
NDC 0944-2850 · Takeda Pharmaceuticals America, Inc.
Key facts
| Product NDC | 0944-2850 |
|---|---|
| Proprietary name | CUVITRU |
| Nonproprietary name | Immune Globulin Subcutaneous (Human) |
| Substances | HUMAN IMMUNOGLOBULIN G |
| Dosage form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Labeler | Takeda Pharmaceuticals America, Inc. |
| Product type | PLASMA DERIVATIVE |
| Marketing category | BLA |
| Application number | BLA125596 |
| Pharmacologic classes | Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE] |
| Marketing start | Oct 18, 2016 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: